About Acumen Pharmaceuticals, Inc.
https://acumenpharm.comAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
CEO
Daniel J. O'Connell
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:14.93M
Value:$26.73M
SANDS CAPITAL VENTURES, LLC
Shares:3.42M
Value:$6.12M
FRANKLIN RESOURCES INC
Shares:2.31M
Value:$4.13M
Summary
Showing Top 3 of 77
About Acumen Pharmaceuticals, Inc.
https://acumenpharm.comAcumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $26.51M ▼ | $-26.45M ▲ | 0% | $-0.44 ▲ | $-25.38M ▲ |
| Q2-2025 | $0 | $41.75M ▲ | $-40.95M ▼ | 0% | $-0.68 ▼ | $-39.86M ▼ |
| Q1-2025 | $0 | $30.37M ▼ | $-28.8M ▲ | 0% | $-0.48 ▲ | $-27.73M ▲ |
| Q4-2024 | $0 | $39.55M ▲ | $-37.15M ▼ | 0% | $-0.62 ▼ | $-36.07M ▼ |
| Q3-2024 | $0 | $32.27M | $-29.77M | 0% | $-0.5 | $-28.69M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $126.61M ▼ | $142.22M ▼ | $49.05M ▼ | $93.17M ▼ |
| Q2-2025 | $143.37M ▼ | $171.9M ▼ | $54.82M ▲ | $117.08M ▼ |
| Q1-2025 | $149.15M ▼ | $204.48M ▼ | $48.96M ▼ | $155.52M ▼ |
| Q4-2024 | $171.56M ▼ | $238.99M ▼ | $57.18M ▲ | $181.82M ▼ |
| Q3-2024 | $200.34M | $266.98M | $49.77M | $217.2M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-26.45M ▲ | $-30.49M ▲ | $40.51M ▲ | $0 | $10.02M ▲ | $-30.49M ▲ |
| Q2-2025 | $-40.95M ▼ | $-31.83M ▲ | $38.48M ▲ | $0 ▲ | $6.65M ▲ | $-31.84M ▲ |
| Q1-2025 | $-28.8M ▲ | $-34.12M ▼ | $28.69M ▼ | $-36K ▼ | $-5.47M ▼ | $-34.2M ▼ |
| Q4-2024 | $-37.15M ▼ | $-27.21M ▼ | $29.66M ▲ | $-9K ▲ | $2.44M ▲ | $-27.21M ▼ |
| Q3-2024 | $-29.77M | $-24.6M | $-10.13M | $-42K | $-34.77M | $-24.6M |
CEO
Daniel J. O'Connell
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 14
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:14.93M
Value:$26.73M
SANDS CAPITAL VENTURES, LLC
Shares:3.42M
Value:$6.12M
FRANKLIN RESOURCES INC
Shares:2.31M
Value:$4.13M
Summary
Showing Top 3 of 77